Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
ApexOnco Front Page
Recent articles
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Jazz’s Chimerix buy faces its big test.
More data from onvansertib's phase 2 study fail to convince.
NT-125 is discontinued, while two key Datroway readouts are delayed.
